Primary hypercholesterolemia: Administered alone or in w/ an HMG-CoA inhibitor (statin) indicated as adjunctive therapy to diet for reduction of elevated total-C, LDL-C, Apo-B & TG, & to increase HDL-C in patients w/ primary (hetrozygous familial & non-familial) hypercholeterolemia. Administered in combination w/ fenofibrate is indicated as adjunctive therapy to diet for reduction of elevated total-C, LDL-C, Apo-B & non-HDL-C in patients w/ mixed hyperlipidemia. Homozygous familial hypercholesterolemia (HoFH): Administered w/ a statin for reduction of elevated total-C & LDL-C levels in patients w/ HoFH.
Patients under fibrates therapy. Liver function tests should be performed at initiation of therapy & according to the recommendations of the statin. Moderate or severe hepatic insufficiency.
Sign Out
